Pharmacological characterization of AMPA-induced biting behaviour in mice

Abstract

The spinal cord dorsal horn contains neural mechanisms which can greatly facilitate pain. It is well established that excitatory amino acids, aspartate and glutamate, are involved in the spinal transmission of nociceptive information and in the development of hyperalgesia. In the present study, intrathecal (i.t.) administration of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), a structural analog of l-glutamate, produced a dose-dependent behavioural syndrome characterized by caudally directed biting in mice. We demonstrated that peripheral pre-administration of the AMPA receptor antagonists 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo( F)quinoxaline (NBQX, 10–100 mg/kg s.c.) and 1-(4-aminophenyl)-3-methylcarbamoyl-4-methyl-3,4-dihydro-7,8-methylene-dioxy-5 H-2,3-benzodiazepine-HCl (GYKI 53655, 3–10 mg/kg s.c.), and also of the NMDA receptor antagonist 5-methyl-10,11-dihydro-5 H-dibenzo[ a,d]cyclohepten-5,10-imine maleate (MK 801, 0.3–1 mg/kg s.c.) reversed this effect. These findings suggest that the hyperalgesia induced by the i.t. injection of AMPA in mice involves the activation of both NMDA and non-NMDA excitatory amino acid receptor sites.